Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 14:14:1213246.
doi: 10.3389/fimmu.2023.1213246. eCollection 2023.

Comparison of C-reactive protein with distinct hyperinflammatory biomarkers in association with COVID-19 severity, mortality and SARS-CoV-2 variants

Affiliations

Comparison of C-reactive protein with distinct hyperinflammatory biomarkers in association with COVID-19 severity, mortality and SARS-CoV-2 variants

Tudorita Gabriela Paranga et al. Front Immunol. .

Abstract

C-reactive protein (CRP) has been one of the most investigated inflammatory-biomarkers during the ongoing COVID-19 pandemics caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The severe outcome among patients with SARS-CoV-2 infection is closely related to the cytokine storm and the hyperinflammation responsible for the acute respiratory distress syndrome and multiple organ failure. It still remains a challenge to determine which of the hyperinflammatory biomarkers and cytokines are the best predictors for disease severity and mortality in COVID-19 patients. Therefore, we evaluated and compared the outcome prediction efficiencies between CRP, the recently reported inflammatory modulators (suPAR, sTREM-1, HGF), and the classical biomarkers (MCP-1, IL-1β, IL-6, NLR, PLR, ESR, ferritin, fibrinogen, and LDH) in patients confirmed with SARS-CoV-2 infection at hospital admission. Notably, patients with severe disease had higher serum levels of CRP, suPAR, sTREM-1, HGF and classical biomarkers compared to the mild and moderate cases. Our data also identified CRP, among all investigated analytes, to best discriminate between severe and non-severe forms of disease, while LDH, sTREM-1 and HGF proved to be excellent mortality predictors in COVID-19 patients. Importantly, suPAR emerged as a key molecule in characterizing the Delta variant infections.

Keywords: COVID-19; CRP; HGF; biomarkers; disease severity; mortality; s-TREM-1; suPAR.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Serum profile of CRP and pro-inflammatory cytokines in mild, moderate and severe COVID-19 disease. (A) Patients’ discharge status (no disease, ameliorated symptoms or deceased) for each category of COVID-19 disease: mild, moderate, severe (***p < 0.001; chi-squared test). Serum levels of (B) CRP, (C) suPAR, (D) sTREM-1, (E) HGF, (F) MCP-1, (G) IL-1β, (H) IL-6 for each category of COVID-19 disease: mild, moderate or severe. The gray lines represent the mean ± SEM (****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05, ns – not significant; (A) chi-squared test; (B-H) Kruskal-Wallis with Dunn’s Multiple Comparison test).
Figure 2
Figure 2
Serum profile of common pro-inflammatory biomarkers in mild, moderate and severe COVID-19 disease. Serum levels of (A) NLR (neutrophil-lymphocyte ratio), (B) PLR (platelet-lymphocyte ratio), (C) ESR (erythrocyte sedimentation rate), (D) fibrinogen, (E) ferritin, (F) LDH for each category of COVID-19 disease: mild, moderate or severe. The gray lines represent the mean ± SEM (****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05, ns – not significant; Kruskal-Wallis with Dunn’s Multiple Comparison test).
Figure 3
Figure 3
Correlation of pro-inflammatory biomarkers with age in mild, moderate and severe SARS-CoV-2 infections. (A) Heat map of correlation coefficients (R) for each category of COVID-19 disease: mild, moderate, severe (0.2-0.39: weak; 0.4-0.59: moderate; 0.6-0.8 strong). (B) CRP levels, (C) suPAR levels, (D) sTREM-1 levels, and (E) NLR values in mild, moderate and severe COVID-19 patients stratified by age (younger or older than 60 years). The gray lines represent the mean ± SEM (***p < 0.001, **p < 0.01, *p < 0.05, ns – not significant; Kruskal-Wallis with Dunn’s Multiple Comparison test).
Figure 4
Figure 4
Regression statistics describing the association between CRP and other pro-inflammatory biomarkers in moderate and severe cases of SARS-CoV-2 infection. (A) Heat map of correlation coefficients (R) for each category of COVID-19 disease: moderate (left-bottom corner) and severe (right-upper corner). Linear regression analysis for (B) CRP and suPAR levels, (C) CRP and sTREM-1 levels, (D) CRP and HGF levels, and (E) sTREM-1 and MCP-1 levels in, moderate and severe COVID-19 patients (****p < 0.0001, **p < 0.01, *p < 0.05, ns – not significant; Spearman test). The blue lines and dots correspond to moderate cases, while the green lines and dots state for severe cases.
Figure 5
Figure 5
Regression statistics describing the association between CRP and classical pro-inflammatory biomarkers in moderate and severe cases of SARS-CoV-2 infection. Linear regression analysis for CRP and (A) ESR, (B) fibrinogen, (C) ferritin, and (D) LDH in moderate and severe COVID-19 patients (****p < 0.0001, ***p < 0.001, **p < 0.01, ns – not significant; Spearman test). The blue lines and dots correspond to moderate cases, while the green lines and dots state for severe cases.
Figure 6
Figure 6
Serum profile of CRP and pro-inflammatory cytokines in Delta and Omicron SARS-CoV-2 infections. Serum levels of (A) suPAR, (B) CRP, (C) sTREM-1, (D) HGF, (E) MCP-1, (F) IL-1β, (G) IL-6 for each category of SARS-CoV-2 infection: Delta or Omicron. The gray lines represent the mean ± SEM (****p < 0.0001, *p < 0.05, ns – not significant; two-tailed Mann-Whitney test). (H) Patients’ discharge status (no disease, ameliorated symptoms or deceased) for each category of SARS-CoV-2 infection: Delta or Omicron (ns – not significant; chi-squared test).
Figure 7
Figure 7
Serum profile of CRP and pro-inflammatory cytokines in severe COVID-19 patients stratified based on survival. Box and whiskers representation of (A) CRP, (B) suPAR, (C) sTREM-1, (D) HGF, (E) MCP-1, (F) IL-1β, (G) IL-6, and (H) LDH serum levels for each category of SARS-CoV-2 severe infection: survived or deceased (**p < 0.01, *p < 0.05, ns – not significant; two-tailed Mann-Whitney test).
Figure 8
Figure 8
Distinct pro-inflammatory biomarkers associate with disease severity, Delta variant infection or increased death rate. (A) Heat map of correlation coefficients of pro-inflammatory biomarkers with disease severity, Delta variant infection or deceased status. ROC curves generated for the (B) association of CRP and other pro-inflammatory biomarkers with severe COVID-19, (C) association of suPAR and other pro-inflammatory biomarkers with Delta variant infection, (D) association of LDH and other inflammatory biomarkers with mortality. The mathematical models from (B–D) are detailed in Supplementary Tables 3–5 , respectively. (E) Kaplan-Meier survival curves for each category of COVID-19 patients: mild, moderate and severe.
Figure 9
Figure 9
Comorbidities associated with COVID-19 severity and mortality. Differences in comorbidity rates (A) between non-severe and severe COVID-19 patients, (B) between survived and deceased COVID-19 patients, and (C) between survived and deceased severe COVID-19 cases (*p < 0.05, ns – not significant; chi-squared test). D = Diseases of the blood involving the immune mechanism (anemia, purpura and other hemorrhagic conditions), E = Endocrine and metabolic disorders, I = Diseases of the circulatory system, K = Diseases of liver and gallbladder.

References

    1. Bollyky TJ, Castro E, Aravkin AY, Bhangdia K, Dalos J, Hulland EN, et al. . Assessing COVID-19 pandemic policies and behaviours and their economic and educational trade-offs across US states from Jan 1, 2020, to July 31, 2022: an observational analysis. Lancet (2023) 401(10385):1341–60. doi: 10.1016/S0140-6736(23)00461-0 - DOI - PMC - PubMed
    1. Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet (2022) 399(10343):2263–4. doi: 10.1016/S0140-6736(22)00941-2 - DOI - PMC - PubMed
    1. Mehta OP, Bhandari P, Raut A, Kacimi SEO, Huy NT. Coronavirus disease (COVID-19): comprehensive review of clinical presentation. Front Public Health (2020) 8:582932. doi: 10.3389/fpubh.2020.582932 - DOI - PMC - PubMed
    1. Mardian Y, Kosasih H, Karyana M, Neal A, Lau CY. Review of current COVID-19 diagnostics and opportunities for further development. Front Med (Lausanne) (2021) 8:615099. doi: 10.3389/fmed.2021.615099 - DOI - PMC - PubMed
    1. Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, et al. . Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med (2021) 26(3):107–8. doi: 10.1136/bmjebm-2020-111536 - DOI - PMC - PubMed

Publication types

Substances

Supplementary concepts